The global hydroxychloroquine market size reached US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.98% during 2024-2032. More Info:- https://www.imarcgroup.com/hydroxychloroquine-market

1. Global Hydroxychloroquine
Market Research and
Forecast Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved

2. About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on management
strategy and market research worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their most critical challenges, and
transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods
are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

3. Report Highlight
and Description
According to the latest report by IMARC Group, titled "Hydroxychloroquine
Market: Global Industry Trends, Share, Size, Growth, Opportunity and
Forecast 2024-2032," the global hydroxychloroquine market size reached US$
1.4 Billion in 2023.
Hydroxychloroquine (HCQ) is a medication that belongs to the class of drugs
known as antimalarials, primarily used for treating and preventing malaria, a
parasitic infection transmitted through mosquito bites. It works by interfering
with the parasites' ability to survive and multiply in the body. In addition to
this, hydroxychloroquine has shown efficacy in managing various autoimmune
diseases.
It is commonly prescribed for rheumatoid arthritis and lupus erythematosus,
where the immune system mistakenly attacks healthy tissues and organs. HCQ
helps suppress the overactivity of the immune system, reducing inflammation
and alleviating symptoms associated with these autoimmune disorders. It is
currently available in tablet and intravenous forms. It is well-absorbed by the
body and reaches therapeutic levels relatively quickly. The dosage and
duration of HCQ vary depending on the specific condition and individual patient
factors.
Request for a PDF sample of this report:
https://www.imarcgroup.com/hydroxychloroquine -market/requestsample

4. Report Description
Global Hydroxychloroquine Market Trends:
The increasing prevalence of malaria around the world is fueling the demand for effective antimalarial drugs, such
as hydroxychloroquine, primarily driving the market growth. Besides this, surging investments in the procurement
and distribution of hydroxychloroquine by various government and healthcare organizations to combat this
infectious disease are positively impacting the market growth. Moreover, the expanding product adoption for
treating and managing autoimmune diseases, such as rheumatoid arthritis and lupus erythematosus, is presenting
remunerative growth opportunities for the market.
In addition to this, the growing use of hydroxychloroquine to treat porphyria cutanea tarda, where an individual
suffers from painful and blistering skin due to sensitivity to sunlight, is acting as another significant growth-
inducing factor. Furthermore, the extensive focus on research and development (R&D) activities in the thriving
pharmaceutical sector to enhance the therapeutic applications of hydroxychloroquine is contributing to the market
growth. Concurrent with this, ongoing studies investigating the potential use of the medication in conditions, such
as cancer, human immunodeficiency virus (HIV), and viral infections, are aiding in market expansion.
Looking forward, the market value is projected to reach US$ 2.5 Billion by 2032, expanding at a CAGR of
6.98% during 2024-2032.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/hydroxychloroquine-market

5. Report
Segmentation
Dosage Type Insights:
• 200 Mg
• 300 Mg
• 400 Mg
• Others
Distribution Insights:
• Hospital Pharmacies
• Retail Pharmacies
• Others
Application Insights:
• Rheumatoid Arthritis
• Lupus Erythematosus
• Malaria
• Coronavirus (COVID-19)
• Others

6. Report
Segmentation
Grade Insights:
• USP Standards Grade
• EP Standards Grade
• Pharmaceutical Standards Grade
• Others
Route of Administration Insights:
• Oral
• Intravenous
Regional Insights:
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7. Competitive
Landscape with
Key Players
• Amneal Pharmaceuticals Inc.
• Cipla Ltd.
• Ipca Laboratories Ltd.
• Laurus Labs
• Lupin Limited
• Mylan N.V.
• Prasco Laboratories
• Dr. Reddy’s Laboratories Ltd.
• Sanofi S.A.
• Teva Pharmaceuticals USA Inc. (Teva
Pharmaceutical Industries Ltd.)
• Torrent Pharmaceuticals Ltd.
• Zydus Lifesciences Limited

8. Key Questions
Answered in
the Report
How has the global hydroxychloroquine market performed so far,
and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global
hydroxychloroquine market?
What is the impact of each driver, restraint, and opportunity on the
global hydroxychloroquine market?
What are the key regional markets?
Which countries represent the most attractive hydroxychloroquine
market?
What is the breakup of the market based on the dosage type?
Which is the most attractive dosage type in the hydroxychloroquine
market?
What is the breakup of the market based on the distribution?
Which is the most attractive distribution in the hydroxychloroquine
market?

9. Key Questions
Answered in
the Report
What is the breakup of the market based on the
application?
Which is the most attractive application in the
hydroxychloroquine market?
What is the breakup of the market based on the
grade?
Which is the most attractive grade in the
hydroxychloroquine market?
What is the breakup of the market based on the
route of administration?
Which is the most attractive route of
administration in the hydroxychloroquine market?
What is the competitive structure of the global
hydroxychloroquine market?
Who are the key players/companies in the global
hydroxychloroquine market?

10. Table of
Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hydroxychloroquine Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Dosage Type
6.1 200 Mg
6.1.1 Mark et Trends
6.1.2 Mark et Forecast
6.2 300 Mg
6.2.1 Mark et Trends
6.2.2 Mark et Forecast
6.3 400 Mg
6.3.1 Mark et Trends
6.3.2 Mark et Forecast

11. Table of
Contents
6.4 Others
6.4.1 Mark et Trends
6.4.2 Mark et Forecast
7 Market Breakup by Distribution
7.1 Hospital Pharmacies
7.1.1 Mark et Trends
7.1.2 Mark et Forecast
7.2 Retail Pharmacies
7.2.1 Mark et Trends
7.2.2 Mark et Forecast
7.3 Others
7.3.1 Mark et Trends
7.3.2 Mark et Forecast
8 Market Breakup by Application
8.1 Rheumatoid Arthritis
8.1.1 Mark et Trends
8.1.2 Mark et Forecast
8.2 Lupus Erythematosus
8.2.1 Mark et Trends
8.2.2 Mark et Forecast
8.3 Malaria
8.3.1 Mark et Trends
8.3.2 Market Forecast
8.4 Coronavirus (COVID -19)
8.4.1 Mark et Trends
8.4.2 Mark et Forecast
For more information, visit :
https://www.imarcgroup.com/hydroxychloroquine -market/toc

12. Disclaimer
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the
name of International Market Analysis Research and Consulting (IMARC). No part of this
publication may be reproduced, repackaged, redistributed or resold in whole or in any part.
The publication may also not be used in any form or by and means graphic electronic or
mechanical, including photocopying, recording, taping or by information storage or retrieval,
or by any other form, without the express consent of International Market Analysis Research
and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and
opinion have been based on information and sources believed to be accurate and reliable at
the time of publishing. International Market Analysis Research and Consulting makes no
representation of warranty of any kind as to the accuracy or completeness of any Information
provided. IMARC accepts no liability whatsoever for any loss or damage resulting from
opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of
International Market Analysis Research and Consulting. All other trademarks used in this
publication are registered trademarks of their respective companies.

13. Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com